CBAY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CBAY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-05), CymaBay Therapeutics's share price is $32.48. CymaBay Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.67. Hence, CymaBay Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for CymaBay Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:
CymaBay Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.23. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.67.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -1.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 7.00% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 2.10% per year.
During the past 12 years, CymaBay Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 31.60% per year. The lowest was -18.40% per year. And the median was -1.90% per year.
The historical data trend for CymaBay Therapeutics's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CymaBay Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
CymaBay Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, CymaBay Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, CymaBay Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where CymaBay Therapeutics's Price-to-Free-Cash-Flow falls into.
CymaBay Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 32.48 | / | -0.665 | |
= | N/A |
CymaBay Therapeutics's Share Price of today is $32.48.
CymaBay Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.67.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
CymaBay Therapeutics (NAS:CBAY) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of CymaBay Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Charles Mcwherter | officer: Chief Scientific Officer | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Daniel Menold | officer: Vice President, Finance | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Paul T Quinlan | officer: General Counsel | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Janet Dorling | director | C/O ACHAOGEN, INC., 1 TOWER PLACE, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Sujal Shah | director, officer: Chief Executive Officer | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Kurt Von Emster | director | 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080 |
Harish Shantharam | officer: Chief Financial Officer | 7575 GATEWAY BLVD, NEWARK CA 94560 |
Dennis D Kim | officer: Chief Medical Officer | C/O EMERALD BIOSCIENCE, INC., 130 NORTH MARINA DRIVE, LONG BEACH CA 90803 |
Eric Lefebvre | director | C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080 |
Thomas G Wiggans | director | |
Lewis J Stuart | officer: Chief Commercial Officer | 3172 PORTER DRIVE, PALO ALTO CA 94304 |
Venbio Select Advisor Llc | 10 percent owner | 110 GREENE STREET, SUITE 800, NEW YORK NY 10012 |
Behzad Aghazadeh | 10 percent owner | C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012 |
Carl Goldfischer | director | 161 WEST 61ST STREET, NEW YORK NY 10022 |
Robert James Wills | director | 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103 |
From GuruFocus
By PRNewswire • 12-15-2023
By Marketwired • 09-15-2023
By GuruFocus Research • 12-16-2023
By Marketwired • 09-06-2023
By PRNewswire • 08-10-2023
By GuruFocus Research • 01-17-2024
By Marketwired • 09-12-2023
By Marketwired • 10-18-2023
By GuruFocus Research • 11-16-2023
By GuruFocus Research • 10-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.